Company Overview and News
U.S. Treasury yields have been somewhat seesawing as multiple factors are impacting the markets at the moment. Despite relatively strong economic fundamentals, trade war fears have made investors question their portfolio allocations and reallocate their assets to counter high volatility.
Thomson Reuters Lipper's fund asset groups (including both mutual funds and ETFs) suffered net outflows of $6.4 billion for the fund-flows week ended Wednesday, April 4. Equity funds (-$11.6 billion) were responsible for the overwhelming majority of the week's net outflows. It was the group's third straight week of negative net flows during which time its coffers shrank $35.6 billion. Taxable bond funds (+$3.
The first month of 2018 was upbeat for the broader market with SPDR S&P 500 ETF (SPY - Free Report) , SPDR Dow Jones Industrial Average ETF (DIA - Free Report) and PowerShares QQQ ETF (QQQ - Free Report) adding about 4.8%, 5.1% and 6.4% as of Jan 30, 2018. There were several developments in the investing backdrop and asset classes.
Beddow Capital Management Inc has disclosed 45 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 245,399,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Beddow Capital Management Inc's top holdings are Mesabi Trust (NYSE:MSB) , Autoliv, Inc. (NYSE:ALV) , TimkenSteel Corporation (NYSE:TMST) , Nestle S.A. (OTC:NSRGY) , and International Business Machines Corp.
The big economic events that just took place were the passage of the Trump tax cut, the rate hike of 0.25% by the Fed with projections to make three more next year, and the ramping up of balance sheet reduction at the Fed. All will have either a dramatic new impact or will add dramatically to prior actions. On the one hand, we have added liquidity into our economy, and on the other hand we have reduced liquidity.
Even though the Federal Reserve hasn't tinkered with the Fed Funds target rate since June, interest rates have been ratcheting upward in anticipation of the next reset. Fed Funds are at the extreme left end - the short end - of the yield curve. The rate applies to overnight interbank loans of excess reserves.
For the second week in three investors were net purchasers of fund assets (including those of conventional funds and ETFs), injecting $6.9 billion. Investors padded the coffers of taxable bond funds (+$3.5 billion), equity funds (+$2.9 billion), money market funds (+$464 million), and municipal bond funds (+$44 million). They remained cautiously optimistic ahead of Q3 2017 earnings season after Congress passed a budget resolution early in the fund-flows week-which many viewed as a precursor to tax-reform legislation.
Scott's Investments provides a free "Dual ETF Momentum" spreadsheet, which was originally created in February 2013. The strategy was inspired by a paper written by Gary Antonacci and available on Optimal Momentum. Antonacci's book, Dual Momentum Investing: An Innovative Strategy for Higher Returns with Lower Risk, also details Dual Momentum as a total portfolio strategy.
Counsel Portfolio Services Inc. has disclosed 294 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 1,010,802,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Counsel Portfolio Services Inc.'s top holdings are iShares 1-3 Year Treasury Bond ETF (NYSE:SHY) , SPDR Barclays International Treasury Bond ETF (NYSE:BWX) , Vanguard FTSE Emerging Markets ETF (NYSE:VWO) , Toronto-Dominion Bank (ON) (NYSE:TD) , and Bank of Nova Scotia (Halifax, NS) (NYSE:BNS) .
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET